Is use of hormone replacement therapy associated with increased detection of human papillomavirus and potential risk of HPV-related genital cancers?

European Journal of Cancer Prevention

Volumn 11, Issue 3, 2002, Pages 295-305

  Smith, Elaine M ^a   Levy, B T ^a   Ritchie, J M ^a   Jia, J ^a   Wang, D ^a   Haugen, T H ^a   Turek, L P ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Human papillomavirus; Postmenopausal; Prevalence

Indexed keywords

ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

ADULT; AGED; CANCER RISK; DRUG USE; FEMALE; GENITAL TRACT CANCER; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VIRUS DETECTION; WART VIRUS; ARTICLE; FEMALE GENITAL TRACT TUMOR; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK; VIRUS INFECTION;

AGED; FEMALE; GENITAL NEOPLASMS, FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RISK; RISK FACTORS; TUMOR VIRUS INFECTIONS;

EID: 0036310633     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008469-200206000-00013     Document Type: Review

References (38)

1. Gapped BLAST and PSI-BLAST: A new generation of protein database search programs
2. The Bethesda System for reporting cervical/vaginal cytologic diagnoses. Report of the 1991 Bethesda Workshop
3. Fast and sensitive silver staining of DNA in polyacrylamide gels
4. Use of postmenopausal hormone replacement therapy: Estimates from a nationally representative cohort study
5. Oral contraceptives and cervical neoplasia
6. Determinants of persistent detection of human papillomavirus DNA in the uterine cervix
7. Progesterone and glucocorticoid response elements occur in the long control region of human papilloma virus-16
8. Human papillomavirus type 16 cooperates with activated ras and fos oncogenes in hormone dependent transformation of primary mouse cells
9. Cigarette smoking and the risk of anogenital cancer
10. The use of general primers GP5 and GP6 elongated at their 3'ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR
11. Benefits and risks of menopausal estrogen and/or progestin hormone use
12. Human papillomavirus infection in postmenopausal women with and without hormone therapy
13. Association of oral contraceptive use and human papillomaviruses in invasive cervical cancers
14. Persistence of type-specific human papillomavirus infection among cytologically normal women
15. Human papillomavirus type 16 and risk of preinvasive and invasive vulvar cancer: Results from a seroepidemiology case-control study
16. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia
17. Effects of long-term hormone replacement therapy on bone in ovariectomized women with cancer
18. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical and squamous intraepithelial lesions
19. Cofactors with human papillomavirus in a population-based study of vulvar cancer
20. Human papillomavirus type 16 DNA cooperates with activated ras oncogene in transforming primary cells
21. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes
22. Risk factors for HPV DNA detection in middle-aged women
23. Oral contraceptive use, human papillomavirus infection, and risk of early cytological abnormalities of the cervix
24. Case-control study of oestrogen replacement therapy and risk of cervical cancer
25. Oncogenic transformation by human papillomavirus type 16 deoxyribonucleic acid in the presence of progesterone or progestins from oral contraceptives
26. Increased prevalence of human papillomavirus in the lower genital tract of pregnant women
27. The association between pregnancy and human papillomavirus prevalence
28. The frequency of human papillomavirus detection in postmenopausal women on hormone replacement therapy
29. A rapid and nonisotopic method for the screening and sequencing of p53 gene mutations in formalin-fixed, paraffin-embedded tumors
30. p53 polymorphism, human papillomavirus infection, and oral cancer
31. Oral contraceptives and invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix. The World Health Organization Collaborative study of neoplasia and steroid contraceptives
32. Postmenopausal estrogens and progestogens and the incidence of gynecologic cancer
33. Short-term fluctuations in the detection of cervical human papillomavirus DNA
34. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal woman: The postmenopausal estrogen/progestin interventions (PEPI) trial
35. Effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial